MODERN TRENDS FOR USE OF PROTECTED AMINOPENICILLINS IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN AMBULATORY PRACTICE


Cite item

Full Text

Abstract

The combination of amoxicillin with clavulanate is used in clinical practice for treatment of respiratory infections for over 30 years. A wide range of antimicrobial activity, including the main respiratory pathogens (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis), and favorable pharmacokinetic and pharmacodynamic (PK/PD) parameters after oral administration provide a high clinical and microbiological efficacy of amoxicillin/clavulanate. At the same time, the occurrence and spread of penicillin-resistant pneumococcal strains have required further optimization of PK/PD parameters of amoxicillin/clavulanate, which led to the creation of new high-dosage form of amoxicillin/clavulanate with modified release of amoxicillin, such as Augmentin SR, registered in Russia in 2010. Review discusses the characteristics of the drug and the prospects its clinical application for acute respiratory infections in adult patients in ambulatory practice.

References

  1. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. МАКМАХ, 2010.
  2. Синопальников А.И., Козлов Р.С., Романовских А.Г. и др. Инфекционное обострение хронической обструктивной болезни легких. Практические рекомендации по диагностике, лечению, профилактике // Рос. мед. вести. 2006. № 11(1). C. 4-18.
  3. Snider GL. Nosology for our day: its application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(5):678-83.
  4. Янов Ю.К., Рязанцев С.В., Страчунский Л.С. и др. Практические рекомендации по антибактериальной терапии синусита. Пособие для врачей // Клин. микробиол. антимикроб. химиотер. 2003. № 5(2). C. 167-74.
  5. Козлов Р.С. Пневмококки: уроки прошлого - взгляд в будущее. МАКМАХ. 2010.
  6. Hadley JA, Pfaller MA. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. Diagn Microbiol Infect Dis 2007;57(3):47-54.
  7. Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002;2:593-604.
  8. Bronzwaer SL, Cars O, Buchholz U, et al. European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8(3):278-82.
  9. Granizo JJ, Aguilar L, Casal J, et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain. J Antimicrob Chemother 2000;46:767-73.
  10. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008;14(11):1722-30.
  11. Stetsiouk OU, Kozlov RS, Poupard JA, et al. Curbing pneumococcal resistance in orphanages: interventions on the basis of prospective surveillance of nasopharyngeal isolates. Clin Microbiol Infect 2006;12(S4):1484.
  12. Stratton CW. Dead bugs don't mutate: susceptibility isues in the emergence of bacterial resistance. Emerg Infect Dis [serial online] 2003 Jan [date cited]. Available from: URL: http://www.cdc.gov/ncidod/EID/vol9no1/02-0175.htm
  13. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным препаратам в России / Под редакцией Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. Смоленск, 2007. С. 32-46.
  14. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC. 2010.
  15. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-004). Diagn Microbiol Infect Dis 2009;63(3):302-0.
  16. Анготоева И.Б. Острые риносинуситы. Как мы следуем стандартам. Материалы VII Конгресса российского общества ринологов "Актуальные вопросы ринологии на современном этапе". Таганрог, 2007.
  17. Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Critical Care 2008;2(4):2.
  18. Pavic-Sladoljev D. Patient compliance in the treatment of respiratory tract infections. K Lijec Vjesn 1997;119:193-200.
  19. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24(1):19-45.
  20. White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53(1):3-20.
  21. Auckenthaler R. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J Antimicrob Chemother 2002;50:13-7.
  22. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7(1):13-20.
  23. File TM Jr, Benninger MS, Jacobs MR. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. Clin Lab Med 2004;24(2):531-51.
  24. Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001;23(4):578-84.
  25. Garau J. Performance in practice: bacteriological efficacy in patients with drug-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2003;9(1):28. Abstract S167.
  26. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate (AMX/CA) 2000/125 mg b.i.d. for 5 days vs AMX/CA 875/125 mg b.i.d. for 7 days in the treatment of acute exacerbations of chronic bronchitis (AECB). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-1592. P. 427.
  27. Richard MP, Wynne B, et al. Clinical safety of pharmacokinetically enhanced amoxicillin/ clavulanate compared with currently approved formulations of amoxicillin/clavulanate. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract 952. Р. 25.
  28. File T, Lode H, Kurz H, et al. Comparative efficacy/safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). 99th International Conference of the American Thoracic Society, Seattle, WA, 2003. Abstract B11. P. A370.
  29. Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007;137 (3):1-31.
  30. World Health Organization. WHO Model Prescribing Information. Drugs used in Bacterial Infections. 2001. WHO, Geneva, Switzerland.
  31. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(2):27-72.
  32. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004;113(5):1451-65.
  33. Augmentin XR, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA, 2002.
  34. File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int J Antimicrob Agents 2002;20(4):235-47.
  35. Anon JB, Berkowitz E, Breton J, et al. Efficacy/safety of amoxicillin/ clavulanate in adults with bacterial rhinosinusitis. Am J Otolaryngol 2006;27(4):248-54.
  36. Garau J, Twynholm M, Garcia-Mendez E, et al. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg b.d. versus amoxicillin/ clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP). 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, April 24-27, 2002.
  37. Petitpretz P, Chidiac C, Soriano F, et al. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002;20(2):119-29.
  38. Каманин Е.И., Стецюк О.У. Инфекции верхних дыхательных путей и ЛОР-органов / Под редакцией Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Антибактериальная терапия. Практическое руководство. М., 2000.
  39. Andes D, Anon J, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004;24(2):477-502.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies